Literature DB >> 19024606

Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.

Tiziana Raso1, Ornella Bianco, Bianca Grosso, Mario Zucca, Dianella Savoia.   

Abstract

Achromobacter xylosoxidans is a ubiquitous Gram-negative non-fermenting rod, recently characterized as an emerging pathogen in cystic fibrosis (CF) patients. Its pathogenic potential and prevalent transmission routes are still unclear. This study investigated the PFGE genetic pattern and antimicrobial resistance profile of 42 A. xylosoxidans isolates obtained over 4 years from the respiratory tract of 22 CF patients. By genotypic analysis, 31 isolates were attributed to 8 distinct PFGE patterns (A-H), whereas 11 isolates were not typable because their DNA was not restricted by XbaI and DraI restriction enzymes. The majority of the isolates showed multidrug resistance; imipenem and piperacillin were the most active drugs. During the course of A. xylosoxidans chronic infection forced expiratory volume and body mass index values were not significantly lowered. The demonstration of widespread antibiotic resistance underscores the importance of antibiogram-directed therapy. Our data suggest that in some cases the infection may have been acquired from other patients or from a common contaminated source. Further epidemiological studies may be important for the design and implementation of prophylactic measures in CF centers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19024606     DOI: 10.1111/j.1600-0463.2008.00995.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  20 in total

Review 1.  Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.

Authors:  Deepak Balasubramanian; Hansi Kumari; Kalai Mathee
Journal:  Pathog Dis       Date:  2015-02-26       Impact factor: 3.166

2.  Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.

Authors:  Rosana H V Pereira; Ana Paula Carvalho-Assef; Rodolpho M Albano; Tania W Folescu; Marcia C M F Jones; Robson S Leão; Elizabeth A Marques
Journal:  J Clin Microbiol       Date:  2011-08-17       Impact factor: 5.948

3.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 4.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

5.  Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans.

Authors:  Winnie Ridderberg; Mikala Wang; Niels Nørskov-Lauritsen
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

6.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

Review 7.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

8.  EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates.

Authors:  Michael Hogardt; Jutta Ulrich; Helga Riehn-Kopp; Burkhard Tümmler
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

9.  Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.

Authors:  A Lambiase; M R Catania; M Del Pezzo; F Rossano; V Terlizzi; A Sepe; V Raia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-31       Impact factor: 3.267

10.  Sphingobacterium respiratory tract infection in patients with cystic fibrosis.

Authors:  Antonietta Lambiase; Fabio Rossano; Mariassunta Del Pezzo; Valeria Raia; Angela Sepe; Fabiola de Gregorio; Maria Rosaria Catania
Journal:  BMC Res Notes       Date:  2009-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.